361 related articles for article (PubMed ID: 34660621)
1. Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing.
Hernández-Juárez J; Rodríguez-Uribe G; Borooah S
Front Med (Lausanne); 2021; 8():698521. PubMed ID: 34660621
[TBL] [Abstract][Full Text] [Related]
2. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
[TBL] [Abstract][Full Text] [Related]
3. Genome-Editing Strategies for Treating Human Retinal Degenerations.
Quinn J; Musa A; Kantor A; McClements ME; Cehajic-Kapetanovic J; MacLaren RE; Xue K
Hum Gene Ther; 2021 Mar; 32(5-6):247-259. PubMed ID: 32993386
[TBL] [Abstract][Full Text] [Related]
4. Gene-Based Therapeutics for Inherited Retinal Diseases.
Fenner BJ; Tan TE; Barathi AV; Tun SBB; Yeo SW; Tsai ASH; Lee SY; Cheung CMG; Chan CM; Mehta JS; Teo KYC
Front Genet; 2021; 12():794805. PubMed ID: 35069693
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy for Inherited Retinal Disorders: Update on Clinical Trials.
Michalakis S; Gerhardt M; Rudolph G; Priglinger S; Priglinger C
Klin Monbl Augenheilkd; 2021 Mar; 238(3):272-281. PubMed ID: 33784790
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10.
Ruan GX; Barry E; Yu D; Lukason M; Cheng SH; Scaria A
Mol Ther; 2017 Feb; 25(2):331-341. PubMed ID: 28109959
[TBL] [Abstract][Full Text] [Related]
7. Gene editing prospects for treating inherited retinal diseases.
Benati D; Patrizi C; Recchia A
J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
[TBL] [Abstract][Full Text] [Related]
8. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.
Maeder ML; Stefanidakis M; Wilson CJ; Baral R; Barrera LA; Bounoutas GS; Bumcrot D; Chao H; Ciulla DM; DaSilva JA; Dass A; Dhanapal V; Fennell TJ; Friedland AE; Giannoukos G; Gloskowski SW; Glucksmann A; Gotta GM; Jayaram H; Haskett SJ; Hopkins B; Horng JE; Joshi S; Marco E; Mepani R; Reyon D; Ta T; Tabbaa DG; Samuelsson SJ; Shen S; Skor MN; Stetkiewicz P; Wang T; Yudkoff C; Myer VE; Albright CF; Jiang H
Nat Med; 2019 Feb; 25(2):229-233. PubMed ID: 30664785
[TBL] [Abstract][Full Text] [Related]
9. New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.
Pulman J; Sahel JA; Dalkara D
CRISPR J; 2022 Jun; 5(3):377-388. PubMed ID: 35506982
[TBL] [Abstract][Full Text] [Related]
10. Visual function restoration in a mouse model of Leber congenital amaurosis via therapeutic base editing.
Jo DH; Jang HK; Cho CS; Han JH; Ryu G; Jung Y; Bae S; Kim JH
Mol Ther Nucleic Acids; 2023 Mar; 31():16-27. PubMed ID: 36589710
[TBL] [Abstract][Full Text] [Related]
11. Prime Editing for the Installation and Correction of Mutations Causing Inherited Retinal Disease: A Brief Methodology.
Tsai YT; da Costa BL; Nolan ND; Caruso SM; Jenny LA; Levi SR; Tsang SH; Quinn PMJ
Methods Mol Biol; 2023; 2560():313-331. PubMed ID: 36481907
[TBL] [Abstract][Full Text] [Related]
12. Prime Editing for Inherited Retinal Diseases.
da Costa BL; Levi SR; Eulau E; Tsai YT; Quinn PMJ
Front Genome Ed; 2021; 3():775330. PubMed ID: 34901928
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for inherited retinal diseases: progress and possibilities.
Hu ML; Edwards TL; O'Hare F; Hickey DG; Wang JH; Liu Z; Ayton LN
Clin Exp Optom; 2021 May; 104(4):444-454. PubMed ID: 33689657
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Therapeutic Evaluation of the Ten Most Prevalent
Lopes da Costa B; Kolesnikova M; Levi SR; Cabral T; Tsang SH; Maumenee IH; Quinn PMJ
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830922
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9-mediated therapeutic editing of
Jo DH; Song DW; Cho CS; Kim UG; Lee KJ; Lee K; Park SW; Kim D; Kim JH; Kim JS; Kim S; Kim JH; Lee JM
Sci Adv; 2019 Oct; 5(10):eaax1210. PubMed ID: 31692906
[TBL] [Abstract][Full Text] [Related]
16. In vivo application of base and prime editing to treat inherited retinal diseases.
Jo DH; Bae S; Kim HH; Kim JS; Kim JH
Prog Retin Eye Res; 2023 May; 94():101132. PubMed ID: 36241547
[TBL] [Abstract][Full Text] [Related]
17. Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases.
Hansen S; McClements ME; Corydon TJ; MacLaren RE
Cells; 2023 Jan; 12(3):. PubMed ID: 36766782
[TBL] [Abstract][Full Text] [Related]
18. Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa.
Diakatou M; Manes G; Bocquet B; Meunier I; Kalatzis V
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126147
[No Abstract] [Full Text] [Related]
19. Personalised genome editing - The future for corneal dystrophies.
Moore CBT; Christie KA; Marshall J; Nesbit MA
Prog Retin Eye Res; 2018 Jul; 65():147-165. PubMed ID: 29378321
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities.
Chien Y; Hsiao YJ; Chou SJ; Lin TY; Yarmishyn AA; Lai WY; Lee MS; Lin YY; Lin TW; Hwang DK; Lin TC; Chiou SH; Chen SJ; Yang YP
J Nanobiotechnology; 2022 Dec; 20(1):511. PubMed ID: 36463195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
